AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Assura PLC

Director's Dealing Aug 31, 2016

4924_rns_2016-08-31_87ad5ab7-5c20-4ccc-ad71-aef412f11915.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6090I

Assura PLC

31 August 2016

31 August 2016

Assura plc

Exercise of Nil Cost Options under VCP

Assura plc ("Assura"), the leading primary care property investor and developer announces that on 30 August 2016, all PDMRs and staff exercised the element of their awards (25% by number) of the Assura Group Value Creation Plan ("VCP") which were exercisable under the Rules of the VCP. The remaining nil cost options are exercisable subject to the achievement of performance hurdles in 2017.

The table below shows the number of nil cost options exercised by PDMRs, the number of shares sold to satisfy Income Tax and National Insurance liabilities and the number of shares they will receive following the sale to satisfy Income Tax and national insurance liabilities.

Number of

Nil Cost Options exercised
Number of shares sold to satisfy Income Tax and National Insurance liabilities Number of shares receivable after sale to satisfy

Income Tax and National Insurance
Jonathan Murphy (Finance Director) 1,288,356 (605,527) 682,829
Andrew Darke 1,472,407 (692,031) 780,376

The Remuneration Committee of Assura had previously agreed that sufficient shares may be sold by PDMRs to cover the arising Income Tax and National Insurance liabilities. The relevant market price for taxation purposes is 58.65 pence per share being the mid-market price at close of business on 26 August.

As a result of the above, the increases in the shareholdings of the PDMRs are as follows:

Shareholding on

29 August 2016
Shareholding

 post exercise
Jonathan Murphy (Finance Director) 957,517 1,640,346
Andrew Darke 378,739 1,159,115

The Notification of Dealing Form for each PDMR can be found below.

This notification is made in accordance with the Market Abuse Regulation. 

Notification of dealing form

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jonathan Murphy

2

Reason for the notification

a)

Position/status

Finance Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Assura plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10 pence each

GB00BVGBWW93

b)

Nature of the transaction

Vesting of share awards under VCP

c)

Price(s) and volume(s)

Price(s) Volume(s)
£NIL GBP 1,288,356

d)

Aggregated information

-      Aggregated volume

-    Price

N/A

e)

Date of the transaction

30 August 2016

f)

Place of the transaction

XLON

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10 pence each

GB00BVGBWW93

b)

Nature of the transaction

Sale of 605,527 shares to satisfy tax and national insurance liabilities.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£0.572 GBP 605,527

d)

Aggregated information

-      Aggregated volume

-    Price

N/A

e)

Date of the transaction

31 August 2016

f)

Place of the transaction

XLON

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Andrew Darke

2

Reason for the notification

a)

Position/status

Property Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Assura plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10 pence each

GB00BVGBWW93

b)

Nature of the transaction

Vesting of share awards under VCP

c)

Price(s) and volume(s)

Price(s) Volume(s)
£NIL GBP 1,472,407

d)

Aggregated information

-      Aggregated volume

-    Price

N/A

e)

Date of the transaction

30 August 2016

f)

Place of the transaction

XLON

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10 pence each

GB00BVGBWW93

b)

Nature of the transaction

Sale of 692,031 shares to satisfy tax and national insurance liabilities.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£0.572 GBP 692,031

d)

Aggregated information

-      Aggregated volume

-    Price

N/A

e)

Date of the transaction

31 August 2016

f)

Place of the transaction

XLON

- Ends -

For more information, please contact:

Assura plc Tel: 01925 420660
Orla Ball

Carolyn Jones
Finsbury Tel: 0207 251 3801
Gordon Simpson

Notes to Editors

Assura plc, a constituent of the FTSE 250, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high quality patient care in the community. At 31 March 2016, Assura's property portfolio was valued at £1,111 million.

Further information is available at www.assuraplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCWGUMCRUPQGAG

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'iFFDWncQqjl-9b2Y8KuoIF3x-gYX0fCjxcfotWOL6cxYwDsAl4ck9qOyNBC4e7qLAceS5_m36wsPTx2KRGTAjeOM-cE9rft1xlcnqkf6WjQ1:LfDPS8PAFFchslaLkv5orbTU4yRaoD_mjCeN1KrjRd1qitt08irBRdZJXNdEm2YNqMENEEjfDbJrOoZtQ5GnL5j0WWkci1Bm4wBl8cD4FDE1'}});//]]>

Talk to a Data Expert

Have a question? We'll get back to you promptly.